Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2026-03-03
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial tests the safety of tagraxofusp when given with or without azacitidine
in patients with acute myeloid leukemia in remission with measurable residual disease who
will undergo allogeneic hematopoietic cell transplant. Tagraxofusp is a recombinant protein
consisting of IL-3 conjugated to a truncated diptheria toxin. The IL-3 attaches to the cancer
cells and the toxic substance kills them. Azacitidine may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Tagraxofusp and azacitidine may work
better to kill cancer cells and eradicate measurable residual disease in patients with acute
myeloid leukemia.